Number of participants who achieved ≥ 90% reduction in PASI compared to baseline.

Logistic regression analysis of PASI 90 response at Week 12

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of body region(head: 0.1, upper limbs: 0.2, trunk: 0.3, lower limbs: 0.4).

The Full analysis set (FAS) is all patients from the randomized set assigned to study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual randomization stratum was different to the assigned stratum in IRT, the actual stratum was used in the analyses.

Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)

The full analysis set (FAS) population was used for this analysis. The FAS included all participants to whom treatment was assigned. Only participants from the FAS, who had values at a given week, were included in the analysis for that week.

Number of participants who achieved ≥ 75% reduction in PASI at Week 12 compared to baseline.

FAS

Number of participants who achieved ≥ 75% reduction in PASI at Week 4 compared to baseline.

FAS

Number of participants who achieved 100% reduction in PASI at Week 16 compared to baseline.

FAS

Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)

The full analysis set (FAS) population was used for this analysis. The FAS included all participants to whom treatment was assigned. Only participants from the FAS, who had values at a given week, were included in the analysis for that week.

Number of participants who achieved 100% reduction in PASI at Week 12 compared to baseline.

FAS

Number of participants who achieved ≥ 75% reduction in PASI at Week 16 compared to baseline.

FAS

Number of participants who achieved ≥ 90% reduction in PASI at Week 16 compared to baseline.

FAS

Number of participants who achieved ≥ 90% reduction in PASI at Week 52 compared to baseline.

FAS